256 related articles for article (PubMed ID: 32510689)
21. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
Li L; Wu Z; Wu M; Qiu X; Wu Y; Kuang Z; Wang L; Sun T; Liu Y; Yi S; Jing H; Zhou S; Chen B; Wu D; Wu W; Liu J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107008. PubMed ID: 33069927
[TBL] [Abstract][Full Text] [Related]
22. Guselkumab for the Treatment of Psoriasis.
Machado Á; Torres T
BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
[TBL] [Abstract][Full Text] [Related]
23. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
Haugh IM; Preston AK; Kivelevitch DN; Menter AM
Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
[TBL] [Abstract][Full Text] [Related]
24. Risankizumab: First Global Approval.
McKeage K; Duggan S
Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
[TBL] [Abstract][Full Text] [Related]
25. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
Papp KA; Blauvelt A; Bukhalo M; Gooderham M; Krueger JG; Lacour JP; Menter A; Philipp S; Sofen H; Tyring S; Berner BR; Visvanathan S; Pamulapati C; Bennett N; Flack M; Scholl P; Padula SJ
N Engl J Med; 2017 Apr; 376(16):1551-1560. PubMed ID: 28423301
[TBL] [Abstract][Full Text] [Related]
26. Tildrakizumab: A Review of Phase II and III Clinical Trials.
Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
[TBL] [Abstract][Full Text] [Related]
27. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
28. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
Paton DM
Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
[TBL] [Abstract][Full Text] [Related]
29. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
Al-Janabi A; Jabbar-Lopez ZK; Griffiths CEM; Yiu ZZN
Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
31. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?
Torres T; Raposo I; Selores M
Am J Clin Dermatol; 2016 Apr; 17(2):107-12. PubMed ID: 26596991
[TBL] [Abstract][Full Text] [Related]
32. A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.
Tonini A; Gualtieri B; Panduri S; Romanelli M; Chiricozzi A
Expert Opin Biol Ther; 2018 Feb; 18(2):135-148. PubMed ID: 29103330
[TBL] [Abstract][Full Text] [Related]
33. Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis.
Hou M; Xing H; Cai Y; Wang X; Xie Z; Zhang Q; Ma Y; Chen J
Eur J Dermatol; 2019 Jun; 29(3):302-314. PubMed ID: 31389789
[TBL] [Abstract][Full Text] [Related]
34. Targeting IL-23 in psoriasis: current perspectives.
Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
Psoriasis (Auckl); 2018; 8():1-5. PubMed ID: 29441315
[TBL] [Abstract][Full Text] [Related]
35. Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients.
Pang Y; Khatri A; Suleiman AA; Othman AA
Clin Pharmacokinet; 2020 Mar; 59(3):311-326. PubMed ID: 31758502
[TBL] [Abstract][Full Text] [Related]
36. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Chiricozzi A; Saraceno R; Chimenti MS; Guttman-Yassky E; Krueger JG
Expert Opin Ther Targets; 2014 May; 18(5):513-25. PubMed ID: 24568095
[TBL] [Abstract][Full Text] [Related]
37. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
38. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
39. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.
Toichi E; Torres G; McCormick TS; Chang T; Mascelli MA; Kauffman CL; Aria N; Gottlieb AB; Everitt DE; Frederick B; Pendley CE; Cooper KD
J Immunol; 2006 Oct; 177(7):4917-26. PubMed ID: 16982934
[TBL] [Abstract][Full Text] [Related]
40. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
